Deike Strobel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Deike Strobel has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Dirk Becker
4 shared publicationsMarkus Frieser
3 shared publications- Daniel Neureiter
Institute of Pathology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria
2 shared publications Eckhart G. Hahn
2 shared publicationsPeter Martus
Department of Medical Informatics, Biometry, and Epidemiology, Benjamin Franklin University, Hindenburgdamm 30, 12200 Berlin, Germany
2 shared publicationsStefan Schaber
2 shared publications
Latest Publications
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Robust Anti-Tumor Response to the Rabbit VX2 Hepatoma by Combined Radio Frequency Ablation and Toll Like Receptor 9 Stimulation
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Robust Anti-Tumor Response to the Rabbit VX2 Hepatoma by Combined Radio Frequency Ablation and Toll Like Receptor 9 Stimulation
- 30 April 2008
- Published by Elsevier in Gastroenterology
- Vol. 134 (4) , A-742-742
W1958 Activation and Increased Cytolytic Activity of Tumor Specific T Lymphocytes After Laser-Induced Thermotherapy (Litt) in Patients with Colorectal Liver Metastases
- 30 April 2008
- Published by Elsevier in Gastroenterology
- Vol. 134 (4) , A-742-742
W1958 Activation and Increased Cytolytic Activity of Tumor Specific T Lymphocytes After Laser-Induced Thermotherapy (Litt) in Patients with Colorectal Liver Metastases
- 26 August 2005
- Published by Georg Thieme Verlag KG in Ultraschall in der Medizin - European Journal of Ultrasound
- Vol. 26 (04) , 270-276
Contrast-Enhanced Sonography for the Characterisation of Hepatocellular Carcinomas - Correlation with Histological Differentiation
Aim: We aimed to characterise the vascularisation patterns of hepatocellular carcinomas in contrast-enhanced sonography in correlation to the histological differentiation of hepatocellular carcinomas (HCC), and we also compared the diagnostic value of contrast-enhanced sonography in addition to B-scan sonography and power Doppler sonography. Methods: 51 hepatocellular carcinomas (21 well differentiated, 27 moderately differentiated, 3 poorly differentiated) were examined: by B-scan sonography, power Doppler sonography and contrast-enhanced sonography using phase or pulse inversion harmonic imaging with a low mechanical index(< 0.3) and second generation microbubble contrast medium (Optison®, Sonovue®) as echo-enhancing agent. Lesion vascularity and the kinetics of contrast enhancement within the lesions in the early arterial phase, arterial phase, portal phase and late phase were analysed. The final diagnosis of a HCC was assessed after B-scan sonography, power Doppler sonography and contrast-enhanced sonography. Results: Hypervascularisation and/or irregular tumour vascularisation could be detected in 18/48 HCCs (37.5 %) by power Doppler sonography. After contrast application, 46/51 HCCs (90.2 %) were identified as hyperechoic lesions during the early arterial or arterial phase with no correlation to histological differentiation. In the portal phase and late phase, the echogenicity of HCCs after contrast application was variable. A hypoechoic appearance was noted in 17/51 HCCs (33.3 %) in the portal phase and in 21/51 HCCs (41.2 %) in the late phase. Moderately differentiated HCCs were more often hypoechoic than well differentiated HCCs (p = 0.04). Conclusion: Contrast-enhanced sonography is highly efficient for the detection of tumour vascularity in HCCs. The majority of HCCs - regardless of histological differentiation - can be characterised as hypervascular lesions in the early arterial and arterial phase with irregular tumour vessels using contrast-enhanced sonography. In addition to B-scan sonomorphology, contrast-enhanced sonography may offer helpful information in patients with liver cirrhosis and focal liver lesions. Ziel: Beschreibung des Vaskularisationsmusters von Karzinomen der Leber bei der kontrastmittelverstärkten Sonographie in Korrelation zum histologischen Differenzierungsgrad dieser hepatozellulären Karzinome (HCC). Der diagnostische Nutzen der Kontrastmittel-Sonographie als Ergänzung zu B-Bild-Sonographie und Power-Doppler-Sonographie wurde ebenfalls untersucht. Methode: Untersucht wurden 51 hepatozelluläre Karzinome (21 gut differenzierte, 27 mäßig differenzierte, 3 undifferenzierte) mittels B-mode-Sonographie, Power-Doppler-Sonographie und kontrastmittelverstärkter Sonographie mit Phasen- oder Puls-Inversions-Technik mit niedrigem mechanischem Index (< 0,3). Kontrastmedium waren die Kontrastmittel der zweiten Generation, Optison® und Sonovue®. Vaskularisierung der Lebertumoren sowie die Kinetik der Kontrastverstärkung innerhalb der Läsionen während der frühen arteriellen Phase, der arteriellen, portalvenösen und der späten Phase wurden analysiert. Die endgültige Diagnose „HCC” wurde nach der Auswertung von B-Bild-Sonographie, Power-Doppler- und kontrastmittelverstärkter Sonographie gestellt. Ergebnisse: Hypervaskularisation und/oder irreguläre Vaskularisierung der Tumoren wurde bei 18/48 hepatozellulären Karzinomen (HCC) durch Power-Doppler festgestellt. Nach Kontrastmittelapplikation konnten 46/51 HCC als echoreiche Läsionen in der frühen arteriellen oder der arteriellen Phase identifiziert werden. Eine Korrelation zum histologischen Differenzierungsgrad wurde hierbei nicht festgestellt. In der portalvenösen und der späten Phase nach Kontrastmittelgabe war die Echogenität der Karzinome uneinheitlich. Bei 17/51 (33,3 %) der hepatozellulären Karzinome fand sich ein echoarmes Muster in der portalvenösen Phase, bei 21/51 (41,2 %) in der späten Phase. Mäßig differenzierte HCC waren häufiger echoarm als gut differenzierte (p = 0,04). Schlussfolgerung: Die kontrastmittelverstärkte Sonographie ist eine hocheffiziente Methode zur Feststellung der Vaskularisation von hepatozellulären Karzinomen. Die Mehrzahl der HCC zeigt sich bei dieser Untersuchung typischerweise als in der früharteriellen und der arteriellen Phase hypervaskularisierte Tumoren mit einem unregelmäßigen Verteilungsmuster der Tumorgefäße. Dieser Befund steht nicht in Beziehung zum histologischen Differenzierungsgrad. Als Ergänzung zur B-Bild-Sonomorphologie kann die kontrastmittelverstärkte Sonographie nützliche Informationen bei Patienten mit Leberzirrhose und fokalen Leberveränderungen bieten.
- 26 August 2005
- Published by Georg Thieme Verlag KG in Ultraschall in der Medizin - European Journal of Ultrasound
- Vol. 26 (04) , 270-276
Contrast-Enhanced Sonography for the Characterisation of Hepatocellular Carcinomas - Correlation with Histological Differentiation
Aim: We aimed to characterise the vascularisation patterns of hepatocellular carcinomas in contrast-enhanced sonography in correlation to the histological differentiation of hepatocellular carcinomas (HCC), and we also compared the diagnostic value of contrast-enhanced sonography in addition to B-scan sonography and power Doppler sonography. Methods: 51 hepatocellular carcinomas (21 well differentiated, 27 moderately differentiated, 3 poorly differentiated) were examined: by B-scan sonography, power Doppler sonography and contrast-enhanced sonography using phase or pulse inversion harmonic imaging with a low mechanical index(< 0.3) and second generation microbubble contrast medium (Optison®, Sonovue®) as echo-enhancing agent. Lesion vascularity and the kinetics of contrast enhancement within the lesions in the early arterial phase, arterial phase, portal phase and late phase were analysed. The final diagnosis of a HCC was assessed after B-scan sonography, power Doppler sonography and contrast-enhanced sonography. Results: Hypervascularisation and/or irregular tumour vascularisation could be detected in 18/48 HCCs (37.5 %) by power Doppler sonography. After contrast application, 46/51 HCCs (90.2 %) were identified as hyperechoic lesions during the early arterial or arterial phase with no correlation to histological differentiation. In the portal phase and late phase, the echogenicity of HCCs after contrast application was variable. A hypoechoic appearance was noted in 17/51 HCCs (33.3 %) in the portal phase and in 21/51 HCCs (41.2 %) in the late phase. Moderately differentiated HCCs were more often hypoechoic than well differentiated HCCs (p = 0.04). Conclusion: Contrast-enhanced sonography is highly efficient for the detection of tumour vascularity in HCCs. The majority of HCCs - regardless of histological differentiation - can be characterised as hypervascular lesions in the early arterial and arterial phase with irregular tumour vessels using contrast-enhanced sonography. In addition to B-scan sonomorphology, contrast-enhanced sonography may offer helpful information in patients with liver cirrhosis and focal liver lesions. Ziel: Beschreibung des Vaskularisationsmusters von Karzinomen der Leber bei der kontrastmittelverstärkten Sonographie in Korrelation zum histologischen Differenzierungsgrad dieser hepatozellulären Karzinome (HCC). Der diagnostische Nutzen der Kontrastmittel-Sonographie als Ergänzung zu B-Bild-Sonographie und Power-Doppler-Sonographie wurde ebenfalls untersucht. Methode: Untersucht wurden 51 hepatozelluläre Karzinome (21 gut differenzierte, 27 mäßig differenzierte, 3 undifferenzierte) mittels B-mode-Sonographie, Power-Doppler-Sonographie und kontrastmittelverstärkter Sonographie mit Phasen- oder Puls-Inversions-Technik mit niedrigem mechanischem Index (< 0,3). Kontrastmedium waren die Kontrastmittel der zweiten Generation, Optison® und Sonovue®. Vaskularisierung der Lebertumoren sowie die Kinetik der Kontrastverstärkung innerhalb der Läsionen während der frühen arteriellen Phase, der arteriellen, portalvenösen und der späten Phase wurden analysiert. Die endgültige Diagnose „HCC” wurde nach der Auswertung von B-Bild-Sonographie, Power-Doppler- und kontrastmittelverstärkter Sonographie gestellt. Ergebnisse: Hypervaskularisation und/oder irreguläre Vaskularisierung der Tumoren wurde bei 18/48 hepatozellulären Karzinomen (HCC) durch Power-Doppler festgestellt. Nach Kontrastmittelapplikation konnten 46/51 HCC als echoreiche Läsionen in der frühen arteriellen oder der arteriellen Phase identifiziert werden. Eine Korrelation zum histologischen Differenzierungsgrad wurde hierbei nicht festgestellt. In der portalvenösen und der späten Phase nach Kontrastmittelgabe war die Echogenität der Karzinome uneinheitlich. Bei 17/51 (33,3 %) der hepatozellulären Karzinome fand sich ein echoarmes Muster in der portalvenösen Phase, bei 21/51 (41,2 %) in der späten Phase. Mäßig differenzierte HCC waren häufiger echoarm als gut differenzierte (p = 0,04). Schlussfolgerung: Die kontrastmittelverstärkte Sonographie ist eine hocheffiziente Methode zur Feststellung der Vaskularisation von hepatozellulären Karzinomen. Die Mehrzahl der HCC zeigt sich bei dieser Untersuchung typischerweise als in der früharteriellen und der arteriellen Phase hypervaskularisierte Tumoren mit einem unregelmäßigen Verteilungsmuster der Tumorgefäße. Dieser Befund steht nicht in Beziehung zum histologischen Differenzierungsgrad. Als Ergänzung zur B-Bild-Sonomorphologie kann die kontrastmittelverstärkte Sonographie nützliche Informationen bei Patienten mit Leberzirrhose und fokalen Leberveränderungen bieten.
- 1 January 2004
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 230 (1) , 169-174
Percutaneous US-guided Radiofrequency Ablation with Perfused Needle Applicators: Improved Survival with the VX2 Tumor Model in Rabbits
PURPOSE: To evaluate survival, metastases, tumor necrosis, and prediction of local recurrence after percutaneous ultrasonographically (US) guided radiofrequency (RF) thermal ablation with electrodes perfused continuously with isotonic saline. MATERIALS AND METHODS: VX2 liver tumors were implanted in 31 rabbits according to a standardized protocol. After 21 days, 16 animals were treated percutaneously with RF ablation. Four animals died of complications related to anesthesia, and 12 animals were evaluated. All animals were followed for 110 days and monitored with computed tomography (CT) and US at 1, 7, and 30 days. A control group of 15 animals did not receive treatment. Autopsy was performed at the end of scheduled follow-up or immediately after death. For survival analysis, the Kaplan-Meier method was used; for nominal data, the Fisher exact test was used. RESULTS: In comparison to controls, animals in the treatment group showed significantly prolonged survival (P < .001). Eight of 12 animals (67%) treated with RF ablation survived to 110 days, while none of the controls did so. Metastases developed in all controls (100%) and in eight of 12 treated animals (67%) (P = .001). In comparison with controls, animals that developed metastases despite treatment also showed significantly prolonged survival (P = .02). Local recurrence was observed in three of 12 animals (25%) in the treatment group. CT and US performed 1 week after treatment did not allow prediction of local recurrence. CONCLUSION: RF ablation of liver tumors with perfused needle applicators prolongs survival in the VX2 rabbit liver tumor model, regardless of whether complete remission is achieved. In comparison with controls, RF ablation results in a lower frequency of metastases. © RSNA, 2003
- 1 January 2004
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 230 (1) , 169-174
Percutaneous US-guided Radiofrequency Ablation with Perfused Needle Applicators: Improved Survival with the VX2 Tumor Model in Rabbits
PURPOSE: To evaluate survival, metastases, tumor necrosis, and prediction of local recurrence after percutaneous ultrasonographically (US) guided radiofrequency (RF) thermal ablation with electrodes perfused continuously with isotonic saline. MATERIALS AND METHODS: VX2 liver tumors were implanted in 31 rabbits according to a standardized protocol. After 21 days, 16 animals were treated percutaneously with RF ablation. Four animals died of complications related to anesthesia, and 12 animals were evaluated. All animals were followed for 110 days and monitored with computed tomography (CT) and US at 1, 7, and 30 days. A control group of 15 animals did not receive treatment. Autopsy was performed at the end of scheduled follow-up or immediately after death. For survival analysis, the Kaplan-Meier method was used; for nominal data, the Fisher exact test was used. RESULTS: In comparison to controls, animals in the treatment group showed significantly prolonged survival (P < .001). Eight of 12 animals (67%) treated with RF ablation survived to 110 days, while none of the controls did so. Metastases developed in all controls (100%) and in eight of 12 treated animals (67%) (P = .001). In comparison with controls, animals that developed metastases despite treatment also showed significantly prolonged survival (P = .02). Local recurrence was observed in three of 12 animals (25%) in the treatment group. CT and US performed 1 week after treatment did not allow prediction of local recurrence. CONCLUSION: RF ablation of liver tumors with perfused needle applicators prolongs survival in the VX2 rabbit liver tumor model, regardless of whether complete remission is achieved. In comparison with controls, RF ablation results in a lower frequency of metastases. © RSNA, 2003
- 1 October 2003
- Vol. 63 (19) , 6496-500
Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits.
Radio-frequency ablation (RFA) is used as a minimally invasive treatment for inoperable hepatic tumors. Immunological reactions secondary to RFA may play a role in the observed tumor control. In our study, the VX2 carcinoma was implanted into the liver of rabbits. After 3 weeks, tumors were treated with RFA or were left untreated. Peripheral blood lymphocytes were harvested before tumor implantation, 2 weeks postoperatively and at 2-week intervals thereafter. T cells were stimulated with lysates of either tumor tissue or nontumorous liver loaded on autologous antigen-presenting cells and their stimulation index was determined by [(3)H]thymidine incorporation. A 3-fold increase over background or controls was considered significant. Stimulation with phytohemagglutinin served as a positive control. The animals were necropsied, and liver and tumor tissue were analyzed immunohistologically for T-cell infiltration. T cells from tumor-bearing (n = 9) and RFA-treated (n = 11) animals were investigated in a follow-up study. The mean postoperative observation was 45 days. All of the 11 RFA-treated animals exhibited circulating T cells activated specifically toward tumor antigens throughout the observation period, which was accompanied by dense T-cell infiltration. In contrast, T cells of untreated tumor-bearing rabbits showed no reaction and only sparse T cell infiltration. We concluded that RFA induces a tumor-specific T-cell reaction in the otherwise unreactive tumor-bearing host, apparently overcoming immune tolerance and leading to the presentation of otherwise cryptic tumor antigens. Therefore, in addition to destroying tumor tissue, RFA induces an immune response against tumor antigens that may be exploited in multimodal antitumor strategies.
- 1 October 2003
- Vol. 63 (19) , 6496-500
Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits.
Radio-frequency ablation (RFA) is used as a minimally invasive treatment for inoperable hepatic tumors. Immunological reactions secondary to RFA may play a role in the observed tumor control. In our study, the VX2 carcinoma was implanted into the liver of rabbits. After 3 weeks, tumors were treated with RFA or were left untreated. Peripheral blood lymphocytes were harvested before tumor implantation, 2 weeks postoperatively and at 2-week intervals thereafter. T cells were stimulated with lysates of either tumor tissue or nontumorous liver loaded on autologous antigen-presenting cells and their stimulation index was determined by [(3)H]thymidine incorporation. A 3-fold increase over background or controls was considered significant. Stimulation with phytohemagglutinin served as a positive control. The animals were necropsied, and liver and tumor tissue were analyzed immunohistologically for T-cell infiltration. T cells from tumor-bearing (n = 9) and RFA-treated (n = 11) animals were investigated in a follow-up study. The mean postoperative observation was 45 days. All of the 11 RFA-treated animals exhibited circulating T cells activated specifically toward tumor antigens throughout the observation period, which was accompanied by dense T-cell infiltration. In contrast, T cells of untreated tumor-bearing rabbits showed no reaction and only sparse T cell infiltration. We concluded that RFA induces a tumor-specific T-cell reaction in the otherwise unreactive tumor-bearing host, apparently overcoming immune tolerance and leading to the presentation of otherwise cryptic tumor antigens. Therefore, in addition to destroying tumor tissue, RFA induces an immune response against tumor antigens that may be exploited in multimodal antitumor strategies.
- 1 January 2003
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 18 (1) , 63-72
Phase inversion harmonic imaging versus contrast-enhanced power Doppler sonography for the characterization of focal liver lesions
- 1 January 2003
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 18 (1) , 63-72
Phase inversion harmonic imaging versus contrast-enhanced power Doppler sonography for the characterization of focal liver lesions
- 30 April 2000
- Published by Elsevier in Gastroenterology
- Vol. 118 (4) , A957
Doppler measurements in patients with chronic viral hepatitis - useful tool for treatment decision?
- 30 April 2000
- Published by Elsevier in Gastroenterology
- Vol. 118 (4) , A957
Doppler measurements in patients with chronic viral hepatitis - useful tool for treatment decision?
- 16 December 1999
- Published by Wiley in Journal of Clinical Ultrasound
- Vol. 28 (1) , 1-13
Clinical evaluation of contrast‐enhanced color Doppler sonography in the differential diagnosis of liver tumors
- 16 December 1999
- Published by Wiley in Journal of Clinical Ultrasound
- Vol. 28 (1) , 1-13
Clinical evaluation of contrast‐enhanced color Doppler sonography in the differential diagnosis of liver tumors